| 0.4491 Data as of 3:59pm ET |  +0.0291 / +6.93%Today’s Change | 0.33 Today|||52-Week Range 1.70 | -27.56% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $23.8M |
Company Description
iBio, Inc. is a biotechnology company which focuses on commercializing its proprietary technology, the iBioLaunch platform, for biologics including vaccines and therapeutic proteins. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants and human blood plasma required by other systems, to produce important biologic pharmaceuticals. The company was founded on April 15, 1993 and is headquartered in Newark, DE.
Employees
Shareholders
| Individual stakeholders | 32.42% |
| Other institutional | 25.92% |
| Mutual fund holders | 1.35% |
Top Executives
| Robert B. Kay | Executive Chairman & Chief Executive Officer |
| Robert L. Erwin | President |
| Scott Kain, CPA | Chief Financial Officer |
| Terence E. Ryan, PhD | Chief Scientific Officer & Senior Vice President |
| Andrea J. Corcoran | Senior Vice President-Finance & Strategy |
.
